Latest Healthcare News

Page 13 of 195
Imugene Limited reports striking early results from its Phase 1b azer-cel trial, achieving a 100% overall response rate in chronic lymphocytic leukemia and 80% in marginal zone lymphoma, while broadening its study to include a BTK inhibitor combination.
Ada Torres
Ada Torres
10 Mar 2026
Dimerix Limited has completed dosing of the last adult patient in its ACTION3 Phase 3 trial for DMX-200, exceeding its recruitment target and setting the stage for key regulatory milestones.
Ada Torres
Ada Torres
10 Mar 2026
Tetratherix Limited has raised approximately $5 million to fast-track its Tutelix prostate spacer into pivotal clinical trials across Australia and the US, aiming to improve radiation therapy for prostate cancer patients.
Ada Torres
Ada Torres
10 Mar 2026
Orthocell has appointed LEDA Orthopaedics as the exclusive distributor for its Remplir™ nerve repair product in the UK, positioning itself for a rapid commercial launch pending regulatory approval.
Ada Torres
Ada Torres
10 Mar 2026
Clarity Pharmaceuticals has completed enrolment in its Phase III AMPLIFY trial for the Cu-SAR-bisPSMA imaging agent, advancing its bid for FDA approval in prostate cancer diagnostics.
Ada Torres
Ada Torres
10 Mar 2026
Telix Pharmaceuticals has announced that Part 1 of its ProstACT Phase 3 trial for TLX591-Tx met its primary safety and dosimetry objectives, with no new safety concerns. The study’s success supports ongoing global enrolment in Part 2 and regulatory engagement in the US.
Ada Torres
Ada Torres
10 Mar 2026
EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.
Ada Torres
Ada Torres
10 Mar 2026
Cyclopharm Limited has responded to ASX queries clarifying the material significance of its Technegas® contract with the US National Institutes of Health, while confirming robust progress in expanding its US footprint.
Ada Torres
Ada Torres
9 Mar 2026
Island Pharmaceuticals has partnered with the Burnet Institute to explore new antiviral applications for its lead drugs, targeting measles, chikungunya, and Ross River virus. This collaboration leverages existing data and government funding to enhance the company’s clinical pipeline without major capital outlay.
Ada Torres
Ada Torres
9 Mar 2026
Rhythm Biosciences has achieved a significant regulatory milestone with NATA accreditation for its ColoSTAT® blood-based colorectal cancer test, enabling its commercial rollout in Australia and strengthening reimbursement prospects.
Ada Torres
Ada Torres
9 Mar 2026
A new clinical study from Sichuan University confirms that TruScreen’s AI-enabled cervical cancer screening combined with high-risk HPV testing outperforms traditional cytology methods, reinforcing its global potential.
Ada Torres
Ada Torres
9 Mar 2026
Pro Medicus Limited’s U.S. subsidiary has locked in two significant 5-year contract renewals worth a combined minimum of A$40 million, reinforcing its position in the competitive medical imaging market.
Ada Torres
Ada Torres
9 Mar 2026